What next for Alzheimer’s research after latest trial failure?

Loading player...
LONDON — Research on Alzheimer’s disease that afflicts an estimated 40m people worldwide has experienced a major setback when pharma company Biogen and its Japanese partner, Eisai announced that they are ending their phase three clinical trials for the drug aducanumab. They concluded that the drug had little chance of succeeding. It wiped almost a third off Biogen’s shares. The end of the trial was a blow for the theory by scientists that the symptoms of Alzheimer’s could be stopped if you manage to clear the build-up of amyloid plaques in ageing brains that destroy connections between nerve cells. And the conclusion at this point, has to be that we really do not know what is causing the disease and how to create an intervention with a pharmaceutical. The likely effect of the Biogen setback is that Big Pharma will retreat from research on Alzheimer’s disease for now, but hopefully this void will be filled by more government and public market funding. Trials are continuing at several universities who are looking at the possibility of using drugs already on the market for diabetes and inflammation, while there are other pharmaceutical companies looking at other approaches to tackle Alzheimer’s, but their research is at a very early stage. Bloomberg’s Carol Massar and Jason Kelly spoke to Senior Biotech Analyst, Asthika Goonewardene and Brian Skorney, Biotech and Pharma Analyst at Baird about the future of Biogen and whether it is time to abandon the amyloid plaque hypothesis. - Linda van Tilburg Learn more about your ad choices. Visit megaphone.fm/adchoices
27 Mar 2019 3AM English South Africa Investing · Business News

Other recent episodes

BN Edge | WSM: Who's steering the ANC during the post-LGE coalition crunch?

With Gauteng's coalition clock running down and the rand slipping towards R17, Cyril Ramaphosa was in California with a 300-strong delegation. William Saunderson-Meyer told Alec Hogg the clash of dates was avoidable, and said it fitted a president with an almost pathological need to dodge conflict in his own party…
18 Nov 8AM 25 min

BN Daybreak: ANC-MK arithmetic; Peche on Nvidia; Cartels lose cover; Market wrap

BizNews editor Alec Hogg says the most underappreciated part of the coalition talks is KwaZulu-Natal, and maps the arithmetic that could give the ANC a majority without the DA: Durban first, then Pietermaritzburg, then Pretoria, where ANC and MK seats add to 217 against the 201 needed. Ranmore founder Sean…
17 Nov 10PM 12 min

BN Edge | Sean Peche: Nvidia, Anthropic, Tencent, Adobe, the rand, the UK

Plenty of investors looked at Nvidia's slump after Jensen Huang's resignation and saw a bargain. Ranmore founder Sean Peche told Alec Hogg he saw a storm. On the day the chipmaker was due to report, he explained why ten times earnings only looked cheap if Nvidia could more than double…
17 Nov 7AM 42 min